文献速递产科母胎医学

妊娠早期母体色氨酸代谢与胚胎及胎儿生长:鹿特丹围受孕期队列(Predict研究)

First trimester maternal tryptophan metabolism and embryonic and fetal growth: the Rotterdam Periconceptional Cohort (Predict Study).
PubMed 文献 · Hum Reprod · 2024-01-01

该研究在鹿特丹围受孕期队列(Predict研究)中纳入1115名妊娠11周前女性,检测妊娠7-11周母体血清色氨酸代谢物,并用三维超声评估胚胎生长。发现母体5-HTP浓度及5-HTP/TRP比值与胚胎生长呈负相关,5-HTP/TRP比值升高与较低估计胎儿体重和出生体重及SGA风险增加相关;而较高KYN浓度在未调整模型中与SGA风险降低相关。

要点

  • 母体5-HTP浓度及5-HTP/TRP比值与胚胎生长(CRL、EV)呈负相关。
  • 母体5-HTP/TRP比值升高与较低EFW和出生体重及SGA风险增加相关(OR=1.006)。
  • 较高母体KYN浓度在未调整模型中与SGA风险降低相关(OR=0.548)。

核心结论

  • 母体5-HTP浓度升高与胚胎和胎儿较小及SGA风险增加相关,提示妊娠早期母体血清素通路紊乱可能参与胎儿生长受限的病理生理。
  • 较高母体KYN浓度与SGA风险降低相关,支持KYN通路在胎儿生长中具有重要作用。
  • 需要更多研究深入探讨母体TRP代谢在围受孕期及妊娠结局中的潜在作用。

研究设计与样本

  • 研究嵌入鹿特丹围受孕期队列(Predict研究),为自2010年11月起在一家三级医院开展的正在进行的 prospective observational cohort。
  • 共纳入1115名于2010年11月至2020年12月间妊娠11周前入组的女性。
  • 母体血清样本于妊娠7至11周采集,采用经过验证的液相色谱(串联)质谱法测定TRP代谢物(TRP、KYN、5-HTP、5-羟色胺和5-羟基吲哚乙酸)。
  • 于妊娠7、9和11周进行系列三维超声扫描,离线使用虚拟现实系统评估胚胎生长特征包括头臀长(CRL)和胚胎体积(EV)。
  • 胎儿生长参数从医疗记录中获取,并根据荷兰参考曲线标准化;采用混合模型评估母体TRP代谢物与CRL和EV轨迹的关联,采用线性和逻辑回归模型分别研究其与估计胎儿体重(EFW)和出生体重及与SGA的关联,所有分析均调整潜在混杂因素。

主要发现

  • 母体5-HTP浓度与胚胎生长呈负相关(5-HTP,√CRL:β = -0.015,95% CI = -0.028至-0.001;5-HTP 3√EV:β = -0.009,95% CI = -0.016至-0.003)。
  • 母体5-HTP/TRP比值升高与较低EFW和出生体重及SGA风险增加相关(OR = 1.006,95% CI = 1.00-1.013)。
  • 较高母体KYN浓度在未调整模型中与SGA风险降低相关(OR = 0.548,95% CI = 0.320-0.921)。

关键数值与推荐

  • 母体5-HTP浓度与√CRL的关联:β = -0.015(95% CI = -0.028至-0.001)。
  • 母体5-HTP浓度与3√EV的关联:β = -0.009(95% CI = -0.016至-0.003)。
  • 母体5-HTP/TRP比值与SGA的关联:OR = 1.006(95% CI = 1.00-1.013)。
  • 母体KYN浓度与SGA的关联(未调整模型):OR = 0.548(95% CI = 0.320-0.921)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 由于本研究的观察性设计,不能排除残余混杂。
  • 此外,本研究在一家三级医院进行,这保证了较高的内部真实性,但可能限制外部真实性。
  • 需要更多研究深入探讨母体TRP代谢在围受孕期及妊娠结局中的潜在作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the association between first trimester maternal tryptophan (TRP) metabolites and embryonic and fetal growth? SUMMARY ANSWER: Higher 5-hydroxytryptophan (5-HTP) concentrations are associated with reduced embryonic growth and fetal growth and with an increased risk of small-for-gestational age (SGA), while higher kynurenine (KYN) concentrations are associated with a reduced risk of SGA. WHAT IS KNOWN ALREADY: The maternal TRP metabolism is involved in many critical processes for embryonic and fetal growth, including immune modulation and regulation of vascular tone. Disturbances in TRP metabolism are associated with adverse maternal and fetal outcomes. STUDY DESIGN, SIZE, DURATION: This study was embedded within the Rotterdam Periconceptional Cohort (Predict Study), an ongoing prospective observational cohort conducted at a tertiary hospital from November 2010 onwards. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 1115 women were included before 11 weeks of gestation between November 2010 and December 2020. Maternal serum samples were collected between 7 and 11 weeks of gestation, and TRP metabolites (TRP, KYN, 5-HTP, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid) were determined using a validated liquid chromatography (tandem) mass spectrometry method. Serial 3D ultrasound scans were performed at 7, 9, and 11 weeks of gestation to accurately assess features of embryonic growth, including crown-rump length (CRL) and embryonic volume (EV) offline using virtual reality systems. Fetal growth parameters were retrieved from medical records and standardized according to Dutch reference curves. Mixed models were used to assess associations between maternal TRP metabolites and CRL and EV trajectories. Linear and logistic regression models were utilized to investigate associations with estimated fetal weight (EFW) and birthweight, and with SGA, respectively. All analyses were adjusted for potential confounders. MAIN RESULTS AND THE ROLE OF CHANCE: Maternal 5-HTP concentrations and the maternal 5-HTP/TRP ratio were inversely associated with embryonic growth (5-HTP, √CRL: β = -0.015, 95% CI = -0.028 to -0.001; 5-HTP 3√EV: β = -0.009, 95% CI = -0.016 to -0.003). An increased maternal 5-HTP/TRP ratio was also associated with lower EFW and birthweight, and with an increased risk of SGA (odds ratio (OR) = 1.006, 95% CI = 1.00-1.013). In contrast, higher maternal KYN concentrations were associated with a reduced risk of SGA in the unadjusted models (OR = 0.548, 95% CI = 0.320-0.921). LIMITATIONS, REASONS FOR CAUTION: Residual confounding cannot be ruled out because of the observational design of this study. Moreover, this study was conducted in a single tertiary hospital, which assures high internal validity but may limit external validity. WIDER IMPLICATIONS OF THE FINDINGS: The novel finding that maternal 5-HTP concentrations are associated with a smaller embryo and fetus implies that disturbances of the maternal serotonin pathway in the first trimester of pregnancy are potentially involved in the pathophysiology of fetal growth restriction. The association between higher maternal KYN concentrations and a reduced risk of SGA substantiate the evidence that the KYN pathway has an important role in fetal growth. More research is needed to delve deeper into the potential role of the maternal TRP metabolism during the periconception period and pregnancy outcome for mother and offspring. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Department of Obstetrics and Gynecology and the Department of Clinical Chemistry of the Erasmus MC, University Medical Center, Rotterdam, the Netherlands. The authors have no competing interests to disclose. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. van Zundert SKM, van Egmond NCM, van Rossem L, et al. First trimester maternal tryptophan metabolism and embryonic and fetal growth: the Rotterdam Periconceptional Cohort (Predict Study). Hum Reprod. 2024. PMID: 38498837. doi:10.1093/humrep/deae046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。